JAMA：血浆中神经降压肽水平或与糖尿病、乳腺癌风险相关

2012年10月10日 讯 /生物谷BIOON/ --刊登在10月10日的国际杂志JAMA上的一篇研究揭示了，妇女机体血浆中神经降压肽（Neurotensin）的水平和糖尿病、心血管疾病、乳腺癌及死亡率直接相关。

神经降压肽是中枢神经系统和胃肠道系统中表达的一种氨基酸肽，其可以调节机体的饱腹感及乳腺癌的发生。但是其在人类乳腺癌和心血管疾病的发病过程中扮演的角色却不得而知。前神经降压肽（Proneurotensin）是机体神经降压肽的前体物质。

来自瑞典隆德大学的研究者检测了血浆中前神经降压肽的水平是否和未来糖尿病、心血管疾病及乳腺癌风险相关。研究者测定并分析了4632位参与者血浆中前神经降压肽的水平。结果显示，前神经降压肽和糖尿病、心血管疾病发病风险相关，尤其是对女性参与者而言，前神经降压肽和糖尿病突发时间、心血管疾病、癌症以及死亡直接相关。

此项研究中，研究者表示，前神经降压肽的评估或许是人们患易感性疾病的一个标志物，当然，作为一项观察性研究，我们的研究结果并不能证明任何前神经降压肽和心肌代谢疾病、乳腺癌发生之间的偶然性事件。（生物谷Bioon.com）

编译自：Hormone Level Linked With Increased Risk of Diabetes, Cardiovascular Disease, Breast Cancer, Death

doi:10.1001/jama.2012.12998
PMC:
PMID:

Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality

Olle Melander et al

Context Neurotensin regulates both satiety and breast cancer growth in the experimental setting, but little is known about its role in the development of breast cancer or cardiometabolic disease in humans.

Objective To test if fasting plasma concentration of a stable 117-amino acid fragment from the neurotensin precursor hormone proneurotensin is associated with development of diabetes mellitus, cardiovascular disease, breast cancer, and mortality.

Design, Setting, and Participants Proneurotensin was measured in plasma from 4632 fasting participants of the population-based Malmö Diet and Cancer Study baseline examination 1991-1994. Multivariate Cox proportional hazards models were used to relate baseline proneurotensin to first events and death during long-term follow-up until January 2009, with median follow-up ranging from 13.2 to 15.7 years depending on the disease.

Main Outcome Measures Incident diabetes mellitus, cardiovascular disease, breast cancer, and mortality.

Results Overall, proneurotensin (hazard ratio [HR] per SD increment of log-transformed proneurotensin) was related to risk of incident diabetes (142 events; HR, 1.28; 95% CI, 1.09-1.50; P = .003), cardiovascular disease (519 events; HR, 1.17; 95% CI, 1.07-1.27; P < .001), and cardiovascular mortality (174 events; HR, 1.29; 95% CI, 1.12-1.49; P = .001) with a significant interaction between proneurotensin and sex ( P < .001) on risk of cardiovascular disease. Exclusively in women, proneurotensin was related to incident diabetes (74 events; HR, 1.41; 95% CI, 1.12-1.77; P = .003), cardiovascular disease (224 events; HR, 1.33; 95% CI, 1.17-1.51; P < .001), breast cancer (123 events; HR, 1.44; 95% CI, 1.21-1.71; P < .001), total mortality (285 events; HR, 1.13; 95% CI, 1.01-1.27; P = .03), and cardiovascular mortality (75 events; HR, 1.50; 95% CI, 1.20-1.87; P < .001).

Conclusion Fasting proneurotensin was significantly associated with the development of diabetes, cardiovascular disease, breast cancer, and with total and cardiovascular mortality.

(责任编辑：yan.mao)